VEGFA and pancreatic neuroendocrine tumor: Upregulation of FGFs by chronic anti-VEGF therapy has been reported in the RIP1-Tag2 mouse (a pancreatic neuroendocrine tumor model) treated by DC101 (an anti-VEGFR2 Ab)11, and in a human head and neck squamous cell carcinoma xenograft tumor model treated by bevacizumab (an anti-VEGFA Ab)12.